Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT07365241
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- NCT07365241 ↗
- Recruiting
- AbbVie
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706; Topotecan; Topotecan; Lurbinectedin; Amrubicin
- Arms
- ABBV-706 · Experimental
- Stand of Care (SOC) · Active comparator
- Enrollment
- 531 (estimated)
- Primary outcomes
- Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- AbbVie
- Start
- Jul 2, 2026
- Primary completion
- Sep 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07365241 · updated Sep 23, 2026